Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.60 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.60 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.49 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25281127 | 0.85 | IDO1 (0.46) | MAPTPIK3CAPIK3CBPIK3CGMEN1 | |
| SCHEMBL27744528 | 0.84 | MAPT (0.51) | MAPTPIK3CAPIK3CBPIK3CGMEN1 | |
| SCHEMBL3251094 | 0.82 | MAPT (0.45) | MAPTPIK3CAPIK3CBPIK3CGMEN1 | |
| SCHEMBL1759878 | 0.82 | MAPT (0.72) | MAPTPIK3CAPIK3CBPIK3CGMEN1 | |
| SCHEMBL446276 | 0.82 | PIK3CA (0.43) | MAPTPIK3CAPIK3CBPIK3CGMEN1 | |
| SCHEMBL3247852 | 0.81 | PIK3CA (0.44) | MAPTPIK3CAPIK3CBPIK3CGMEN1 | |
| SCHEMBL4809419 | 0.81 | MAPT (0.83) | MAPTPIK3CAPIK3CBPIK3CGMEN1 | |
| SCHEMBL3253724 | 0.80 | PDE2A (0.46) | MAPTPIK3CAPIK3CBPIK3CGMEN1 | |
| SCHEMBL319801 | 0.79 | CYP19A1 (0.51) | MAPTPIK3CAPIK3CBPIK3CGMEN1 | |
| SCHEMBL447060 | 0.77 | CYP19A1 (0.47) | SMN1; SMN2NPC1RAB9AL3MBTL1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2613775-B1 | N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2014-07-30 | — | — | EP | disclosed |
| US-8716285-B2 | N-hydroxy-benzamids for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2613775-A1 | NOVEL N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120065204-A1 | NOVEL N-HYDROXY-BENZAMIDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| WO-2012031993-A1 | NOVEL N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065204-A1 | NOVEL N-HYDROXY-BENZAMIDS FOR THE TREATMENT OF CANCER | HNMT, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRAS | MAPT 4852/4885PIK3CA 1728/4885PIK3CB 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.